A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

NCT02613650 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Advanced KRAS Positive Metastatic Colorectal Cancer

Interventions

DRUG: MEK162 and mFOLFIRI

Sponsor

University of Utah

Collaborators

[object Object]